The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

Highlighting the event is the immersive simulation, “Seeing Beyond the Ordinary and Repairing Damages,” led by world-renowned ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

The collaboration will focus on preventive solutions, workshops, and public awareness. King Faisal Specialist Hospital and ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

It's a daycare procedure and doesn't require hospitalisation. However, it is an expensive treatment. Will my health insurance ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...

Striking a balance between innovation and responsibility is imperative. By prioritizing transparency, adhering to robust ...

Avoid the most common diabetes complications with these helpful tips. Insulin is the main treatment for type 1 and 1.5 diabetes. It replaces the hormone your body isn’t able to produce.

Retinopathy outcomes were further three or more–step retinopathy progression (or just "progression") from the level at DCCT closeout, new severe nonproliferative diabetic retinopathy (SNPDR ...